Susan Hill, Mestag CEO

J&J, GV back a new sin­gle-cell ap­proach for tack­ling in­flam­ma­to­ry dis­eases and hack­ing the tu­mor mi­croen­vi­ron­ment

Most biotechs try­ing to tack­le in­flam­ma­to­ry dis­or­ders like IBD or at­tempt­ing to boost the po­ten­cy of im­munother­a­pies for can­cer have fo­cused, log­i­cal­ly, on tar­get­ing, block­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.